Breakfast Briefing |
Thursday, August 28, 2025

7:30 am Breakfast Briefing Registration

BREAKFAST BRIEFING

8:00 am Building A Go-To-Market Strategy with Value for All Players & Stakeholders in Rare Disease

  • Rebecca Derwin Global Commercial Lead – Gamifant, Sobi
  • Liz Arnold Head of Commercial Strategy, BridgeBio Pharma, Inc.
  • Jessica Gall Director Global Product Strategy, BioMarin Pharmaceutical

Synopsis

Unlike traditional pharmaceuticals, rare disease commercialization requires a deeply specified roadmap, where patient engagement, access strategies, and regulatory navigation must be customized to the nuances of each disorder, making templated approaches ineffective.

  • How to plan and create road maps to a successful commercial strategy
  • How best to assess treatment guidelines, current treatments & regulations to inform early strategy
  • How to quality check commercial strategy planning to ensure success further down the line
  • Learning from past successes and failures in rare disease commercialization to refine forecasting and strategic decision-making

10:00 am End of Breakfast Briefing